Stockscreener 앱 받기
2.84%
전일 마감가:
$4.05
열려 있는:
$4.03
하루 거래량:
1.84M
Relative Volume:
0.68
시가총액:
$348.17M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.4015
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-4.95%
1개월 성능:
+0.64%
6개월 성능:
-31.80%
1년 성능:
-41.62%
1일 변동 폭
$3.925
$4.05
1주일 범위
$3.925
$4.25
52주 변동 폭
$2.90
$11.16
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
ALT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.945 | 357.44M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.27 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.15 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.02 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.35 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.61 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Altimmune completes enrollment for alcohol use disorder trial - Investing.com
Altimmune (ALT) Completes Enrollment for Phase 2 AUD Trial - GuruFocus
Altimmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Clinical Trial for Pemvidutide in Alcohol Use Disorder - Quiver Quantitative
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - The Manila Times
Will Altimmune Inc. stock reach all time highs in 2025Weekly Loss Report & Verified Momentum Stock Ideas - newser.com
Should you wait for a breakout in Altimmune Inc.Stop Loss & Low Drawdown Investment Strategies - newser.com
Altimmune Inc. stock chart pattern explainedQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
How strong is Altimmune Inc. stock revenue growthGlobal Markets & Weekly Momentum Stock Picks - newser.com
Why Altimmune Inc. stock is a value investor pickTrade Entry Report & AI Forecasted Stock Moves - newser.com
Using AI based signals to follow Altimmune Inc.July 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
How Altimmune Inc. stock performs during Fed tightening cyclesMarket Risk Analysis & Free Low Drawdown Momentum Trade Ideas - newser.com
Technical analysis overview for Altimmune Inc. stockEarnings Trend Report & Precise Trade Entry Recommendations - newser.com
Altimmune (ALT) to Release Quarterly Earnings on Thursday - MarketBeat
Tools to monitor Altimmune Inc. recovery probability2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Automated trading signals detected on Altimmune Inc.2025 Volume Leaders & Safe Capital Growth Trade Ideas - newser.com
Moody Aldrich Partners LLC Invests $610,000 in Altimmune, Inc. $ALT - MarketBeat
Can technical indicators confirm Altimmune Inc.’s reversalMarket Risk Report & Weekly High Return Stock Opportunities - newser.com
How to use Fibonacci retracement on Altimmune Inc.Weekly Stock Report & Consistent Profit Trade Alerts - newser.com
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Forecasting Altimmune Inc. price range with options dataFed Meeting & Risk Managed Investment Entry Signals - newser.com
How to forecast Altimmune Inc. trends using time seriesWatch List & Free Risk Controlled Daily Trade Plans - newser.com
What technical charts say about Altimmune Inc. stockQuarterly Earnings Report & Reliable Price Breakout Signals - newser.com
What MACD and RSI say about Altimmune Inc.2025 Market Trends & Detailed Earnings Play Strategies - newser.com
Using fundamentals and technicals on Altimmune Inc.Risk Management & Community Consensus Stock Picks - newser.com
Can momentum traders help lift Altimmune Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress (NASDAQ:ALT) - Seeking Alpha
Does Altimmune Inc. show high probability of reboundJuly 2025 Fed Impact & High Yield Equity Trading Tips - newser.com
Altimmune (Nasdaq: ALT) schedules Nov 6 results call at 8:30 a.m. ET with business update - Stock Titan
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
0.15%
1.65%
자본화:
|
볼륨(24시간):